Int J Spine Surg. 2026 Mar 16:8860. doi: 10.14444/8860. Online ahead of print.
ABSTRACT
BACKGROUND: Investigational device exemption (IDE) studies for spine technologies have evolved significantly since the early 2000s, when traditional randomized controlled trials (RCTs) established a specific regulatory framework for lumbar total disc replacement. Modern clinical trial designs are pragmatic and can address escalating costs (lumbar fusion costs increased 177% between 2004 and 2015), patient enrollment challenges, and evolving regulatory acceptance of alternative evidence standards. Following the 21st Century Cures Act, the US Food and Drug Administration has increasingly accepted real-world evidence (RWE) in regulatory decision-making, fundamentally reshaping the landscape for medical device development. This perspective examines how modern IDE trials integrate RWE to address economic and practical barriers while maintaining scientific validity.
METHODS: We reviewed the evolution of clinical trial designs for lumbar motion preservation technologies from 2000 to 2025 and analyzed the methodological framework of the MOTUS lumbar total joint replacement IDE study. This modern trial design employs prospective dual-arm enrollment with an investigational lumbar total joint replacement arm and an independent RWE control arm documenting transforaminal/posterior lumbar interbody fusion outcomes under standard-of-care conditions. Prespecified design elements included identical sites and surgeons enrolling in identical overlapping intervals, standardized outcome measures, propensity score adjustment for potential confounding, and adaptive sample size allowing for mid-study adjustment.
RESULTS: Modern trial designs incorporating RWE demonstrate substantial advantages over traditional RCTs for spine device evaluation. The MOTUS IDE substantially completed enrollment in 3.5 years vs 4 to 5 years for historical lumbar total disc replacement RCTs. Insurance coverage of standard-of-care procedures in the RWE arm reduced sponsor costs 5- to 10-fold compared with sponsor-funded control arms in traditional RCTs. The design foregoes inherent limitations of spine device RCTs, including the inability to blind participants and patient reluctance to accept randomization to nonmotion preservation techniques (eg, implantation of fusion hardware), while preserving comparative validity through propensity score methodology validated across multiple regulatory submissions.
CONCLUSIONS: Incorporating RWE in a clinical trial approach enables resource-constrained innovators to advance novel technologies through the Premarket Approval pathway, addressing a critical gap in medical technology innovation, as large manufacturers have withdrawn from lumbar motion preservation development.
CLINICAL RELEVANCE: This perspective provides insight into the challenges of clinical trials for novel motion-preserving spine technologies.
PMID:41839575 | DOI:10.14444/8860
